Gedeon Richter Introduces Siluet Contraceptive Pill
Gedeon Richter Plc. has launched Siluet, a new low-dose combined oral contraceptive pill containing dienogest and ethinylestradiol. The medication is intended for pregnancy prevention.
Budapest – Pharmaceutical company Gedeon Richter Plc. has introduced Siluet, a new contraceptive medication. This is a low-dose, monophasic combined oral contraceptive (COC) containing two types of female sex hormones: dienogest (a progestogen) and ethinylestradiol (an estrogen).
The primary use of Siluet is to prevent pregnancy. Its contraceptive effect is achieved through a combination of complementary mechanisms, notably the suppression of ovulation and an increase in the viscosity of cervical mucus, making it difficult for sperm to penetrate. For users, this can also lead to more regular and less painful menstrual cycles.
Gedeon Richter advises that patients read the patient information leaflet thoroughly before use. It is crucial for individuals to consult with their healthcare provider about any personal medical history, including factors that could increase the risk of blood clots, as detailed contraindications are listed.
The company, Gedeon Richter, is an international pharmaceutical and biotechnology company headquartered in Hungary, with a significant focus on women's healthcare. This product launch expands its portfolio in the reproductive health sector.